Iridex Introduces New Research and Showcases Five Events at the AGS Meeting

Rhea-AI Summary

Iridex Corporation (NASDAQ: IRIX) announced the publication of Part 2 of the evidence-based guidelines for MicroPulse Transscleral Laser Therapy (TLT) at the 2023 American Glaucoma Society meeting in Austin, Texas. This guide, created by a panel of ten glaucoma experts, covers critical aspects such as anesthesia, surgical technique, and expected outcomes. It builds on Part 1, focusing on dosimetry and patient selection. Attendees can also view Dr. Syril Dorairaj's e-poster on MicroPulse TLT outcomes and demo the Sweep Management Software designed to optimize surgical techniques. Iridex continues to lead in ophthalmic laser-based treatments.

Positive

• Publication of Part 2 evidence-based guidelines for MicroPulse TLT enhances credibility.
• Improved guidelines are based on 100% consensus among top glaucoma experts.
• Demos of advanced Sweep Management Software available to optimize surgical procedures.

Negative

• None.

Five Events at Booth #5

1. Discover the latest surgical techniques and outcomes published by the International MicroPulse TLT Consensus Panel.
2. Watch Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes.
3. Demo Sweep Management Software for MicroPulse TLT.
4. Celebrate AGS Innovator Award recipient Douglas Gaasterland, MD.
5. Learn about our Advanced Surgeon Forum on MicroPulse TLT.

MOUNTAIN VIEW, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced Part 2 of the evidence-based guidelines series for MicroPulse Transscleral Laser Therapy (TLT) has been published in Clinical Ophthalmology¹ by the international consensus panel of ten glaucoma experts. The publication will be available at booth #5 at the 2023 meeting of the American Glaucoma Society (AGS), March 2 -5 in Austin, Texas.

More info on the consensus and Iridex at AGS:

Consensus Panel Recommendations
Part 2 recommendations address anesthesia, surgical technique, post-operative care, expected outcomes, settings adjustment, and enhancements and retreatments.² Part 1 of the consensus recommendations, published in 2021, focused on patient dosimetry and patient selection.² The recommendations, which are confirmed as 100% consensus among the experts, are the result of a complete analysis of MicroPulse TLT clinical, technical, and practical experience to date.

“As physicians gathered further experience and conducted additional research on MicroPulse TLT, a better understanding of all aspects of the treatment helped improve the procedure and optimize outcomes,” said Tomas Grippo, MD, co-chair of the International MicroPulse TLT Consensus Panel. “We are pleased to provide additional guidelines for a treatment we have found to be safe and effective for many types and severities of glaucoma.”

The recommendations provide a valuable foundation for learning how to maximize the safety and effectiveness of this non-incisional procedure performed with the Cyclo G6^® Laser and revised MicroPulse P3^® Delivery Device. The revised device has improved ergonomics that support more stable positioning during treatment and facilitates a more posterior application of laser energy, keeping it farther from anterior segment structures.^2,3

Copies of the paper will be distributed free at the Iridex booth. To watch the expert panel discuss its findings, visit www.iridex.com/consensus to view Part 1 and Part 2 of the consensus webinar series, or download the white paper here.

Hear Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes

Dr. Syril Dorairaj and colleagues present their e-poster, “Clinical Outcomes of MicroPulse Transscleral Laser Therapy: A Prospective Cohort Study.” Check the AGS program for more details.

Demo our Sweep Management Software for MicroPulse TLT
MicroPulse TLT is a versatile, non-incisional and repeatable procedure for the treatment of glaucoma performed with the Iridex Cyclo G6^® Laser System and MicroPulse P3^® Delivery Device. The Cyclo G6 now provides Sweep Management Software, which allows surgeons to tailor an optimized therapeutic dose for delivering MicroPulse TLT. Demos are available at the Iridex booth where physicians can learn how to improve their surgical technique and consistency in application.

Help us celebrate!
We invite AGS attendees to stop by the Iridex booth #5 to sign a super-sized card to congratulate Dr. Douglas Gaasterland, the AGS Innovator Award recipient, for his pioneering contributions to glaucoma and ophthalmology. We are honored to have collaborated with Dr. Gaasterland in his pioneering work on the advancement of transscleral cyclophotocoagulation and the development of the Iridex G-Probe^®.

Join our next Iridex Academy webinar on MicroPulse TLT Register for our March Iridex Academy webinar at iridex.com/training to join host Dr. Brian Francis for an advanced peer-to-peer surgeon forum on MicroPulse TLT.

References

1. Grippo TM, et al. Evidence-based consensus guidelines series for micropulse transscleral laser therapy - surgical technique, post-operative care, expected outcomes and retreatment/enhancements. Clin Ophthalmol 2023;17:71-83.
2. Grippo TM, et al. Evidence-based consensus guidelines series for micropulse transscleral laser therapy: Dosimetry and patient selection. Clin Ophthalmol 2022;16:1837-1846.
3. Checo L, et al. Prospective comparison of different energy parameters of micropulse transscleral laser therapy. Presented at American Glaucoma Society Annual Meeting; 2022; Nashville, TN.

About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight-threatening eye conditions. Iridex’s products are used to treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit https://www.iridex.com/.

Iridex Media Contact
Jamie Hall
PRECISIONeffect
724.417.0167
jamie.hall@precisionvh.com

FAQ

What are the new guidelines for MicroPulse TLT published by Iridex in 2023?

Part 2 of the guidelines covers anesthesia, surgical technique, post-operative care, and expected outcomes.

When and where was the Iridex MicroPulse TLT event held?

The event took place at the American Glaucoma Society meeting from March 2-5, 2023, in Austin, Texas.

What is the significance of the consensus guidelines for MicroPulse TLT?

The guidelines offer a comprehensive framework to improve safety and effectiveness of the treatment, confirmed by leading glaucoma experts.

Who presented research outcomes at the AGS meeting related to MicroPulse TLT?

Dr. Syril Dorairaj presented an e-poster on prospective MicroPulse TLT dosimetry research outcomes.

What technology does Iridex use for MicroPulse TLT?

Iridex employs the Cyclo G6 Laser and MicroPulse P3 Delivery Device for the procedure.